Humacyte Change To Netincome Over Time
| HUMA Stock | USD 4.49 0.11 2.51% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Humacyte Performance and Humacyte Correlation. Humacyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change To Netincome Analysis
Compare Humacyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Change To Netincome Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNX | 270 K | 270 K | 270 K | 270 K | 270 K | 270 K | 270 K | 271 K | 1.9 M | 6.3 M | 10.5 M | 17 M | 29.1 M | 33.5 M | 35.2 M |
| VRDN | 640 K | 640 K | 640 K | 640 K | 640 K | 640 K | 640 K | 2.5 M | 3.6 M | 3.9 M | 76 M | 22 M | 19.8 M | 22.7 M | 20.2 M |
| CYTK | 3.3 M | 3.3 M | 3.7 M | 3.5 M | 3.3 M | 4.5 M | 7.7 M | 9 M | 9.8 M | 11.7 M | 23.7 M | 34 M | 78.6 M | 90.4 M | 94.9 M |
| GPCR | 624 K | 624 K | 624 K | 624 K | 624 K | 624 K | 624 K | 624 K | 624 K | 624 K | 624 K | 1.7 M | 2 M | 2.2 M | 1.6 M |
| IMCR | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (5.7 M) | (19.3 M) | 3.4 M | 33.3 M | 45.4 M | 22.1 M | 25.4 M | 26.7 M |
| MIRM | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 5.7 M | 12.6 M | 23.1 M | 27 M | 31.1 M | 19.8 M |
| LRMR | 173 K | 173 K | 173 K | 173 K | 173 K | 173 K | 173 K | 173 K | 173 K | 129 K | 2.2 M | 5.5 M | 6.6 M | 7.6 M | 8 M |
| KALV | 36 K | 36 K | 36 K | 36 K | 36 K | 3.4 M | (977 K) | 409 K | 2.9 M | 4.2 M | 6.4 M | 13.2 M | 8.4 M | 3.4 M | 3.8 M |
| LYRA | (772 K) | (772 K) | (772 K) | (772 K) | (772 K) | (772 K) | (772 K) | (772 K) | (772 K) | 411 K | 1.8 M | 2.8 M | 6.3 M | 7.2 M | 7.6 M |
| KURA | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 3.3 M | 2.3 M | 4.4 M | 9.2 M | 9.4 M | 12.8 M | 24.2 M | 26.4 M | 30.3 M | 31.9 M |
| NRIX | 71 K | 71 K | 71 K | 71 K | 71 K | 71 K | 71 K | 71 K | 401 K | 4.6 M | 17.6 M | 28.3 M | 28.3 M | 32.6 M | 34.2 M |
| SEER | 672 K | 672 K | 672 K | 672 K | 672 K | 672 K | 672 K | 672 K | 672 K | 1.3 M | 7.6 M | 25.9 M | 34.5 M | 39.7 M | 41.7 M |
| QSI | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 1.9 M | 25.7 M | 14.7 M | 16.9 M | 12.5 M |
| HCWB | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 21.9 K | (140.5 K) | 1.3 M | 1.5 M | 1.6 M |
| MNOV | 1.4 M | 1.4 M | 710.5 K | 1.2 M | 1.6 M | 2.1 M | 4 M | 4.5 M | 6.3 M | 4.1 M | 3.2 M | 1.7 M | 765 K | 879.7 K | 835.8 K |
Humacyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Change To Netincome description
My Equities
My Current Equities and Potential Positions
| Humacyte | HUMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | North Carolina; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.49
Check out Humacyte Performance and Humacyte Correlation. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Humacyte technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.